Compare Bristol-Myers Squibb Co (BMY) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Entegris Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Entegris Inc trades at $144.38 (market cap $21.42B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.4× Entegris Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | ENTG | |
|---|---|---|
Market Cap | $116.30B | $21.42B |
Sector | Health | Technology |
52-Week High | $62.37 | $184.00 |
52-Week Low | $42.60 | $68.80 |
Enterprise Value | $152.24B | $24.73B |
Dividend Yield | 4.42% | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ENTG trades at $136.27, down 6.25% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 78.77 but strong recent earnings beats. Revenue remains stable at $3.2B with improving net margins. Analyst consensus is bullish with a $178.40 price target, representing 31% upside potential. Recent developments include a new CFO appointment and strategic licensing agreements in semiconductor technology.
ENTG presents a compelling growth story in semiconductor materials with AI-driven demand catalysts, though premium valuation and technical weakness create near-term headwinds. The company's positioning in advanced chip manufacturing and consistent earnings performance support long-term upside, while current price levels offer entry opportunity below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
